Related references
Note: Only part of the references are listed.Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
Stephen Yip et al.
JOURNAL OF PATHOLOGY (2012)
Initial treatment patterns over time for anaplastic oligodendroglial tumors
Katherine S. Panageas et al.
NEURO-ONCOLOGY (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2011)
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Chetan Bettegowda et al.
SCIENCE (2011)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
COGNITION AND QUALITY OF LIFE AFTER CHEMOTHERAPY PLUS RADIOTHERAPY (RT) VS. RT FOR PURE AND MIXED ANAPLASTIC OLIGODENDROGLIOMAS: RADIATION THERAPY ONCOLOGY GROUP TRIAL 9402
Meihua Wang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Update on molecular findings, management and outcome in low-grade gliomas
T. David Bourne et al.
NATURE REVIEWS NEUROLOGY (2010)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Survey of treatment recommendations for anaplastic oligodendroglioma
Lauren E. Abrey et al.
NEURO-ONCOLOGY (2007)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
K Hoang-Xuan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971
MJ van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Influence of unrecognized molecular heterogeneity on randomized clinical trials
RA Betensky et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy
OL Chinot et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
JS Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
